Literature DB >> 35900713

Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents.

Harshita Sachdeva1, Sarita Khaturia2, Mohammad Saquib3, Narsingh Khatik4, Abhinav Raj Khandelwal4, Ravina Meena4, Khushboo Sharma4.   

Abstract

Oxygen- and sulphur-based heterocycles form the core structure of many biologically active molecules as well as U.S. FDA-approved drugs. Moreover, they possess broad range of biological activities, viz. anticancer, antiinflammatory, antioxidant, antitumour, antibacterial, antiviral, antidiabetic, anticonvulsant, anti-tubercular, analgesic, anti-leishmanial, antimalarial, antifungal, and anti-histaminic, Hence, O- and S-based heterocycles are gaining more attention in recent years on the road to the discovery of innovative anticancer drugs after the extensive investigation of nitrogen-based heterocycles as anticancer agents. Several attempts have been made to synthesize fused oxygen- and sulphur-based heterocyclic derivatives as joining one heterocyclic moiety with another may lead to improvement in the biological profile of a molecule. Humans have been cursed with cancer since long time. Despite the development of several heterocyclic anticancer medications such as 5-fluorouracil, doxorubicin, methotrexate, and daunorubicin, cure of cancer is difficult. Hence, researchers are trying to synthesize new fused/spiro heterocyclic molecules to discover novel anticancer drugs which may show promising anticancer effects with fewer side effects. Furthermore, fused heterocycles behave as DNA intercalating agents which have the ability to interact with DNA, leading to cell death thereby exerting anticancer effect. This review article highlights the synthesis and anticancer potentiality of oxygen- and sulphur-containing heterocyclic compounds covering the period from 2011 to 2021.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anticancer agents; Heterocyclic compounds; Oxygen-based; Sulphur-based

Year:  2022        PMID: 35900713     DOI: 10.1007/s12010-022-04099-w

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   3.094


  59 in total

Review 1.  Role of sulphur-heterocycles in medicinal chemistry: An update.

Authors:  Shelly Pathania; Raj Kumar Narang; Ravindra K Rawal
Journal:  Eur J Med Chem       Date:  2019-07-15       Impact factor: 6.514

2.  Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.

Authors:  Glenn Liu; Yu-Hui Chen; Robert Dipaola; Michael Carducci; George Wilding
Journal:  Clin Genitourin Cancer       Date:  2012-03-03       Impact factor: 2.872

3.  A Comprehensive Review on Fused Heterocyclic as DNA Intercalators: Promising Anticancer Agents.

Authors:  Vikas Sharma; Mohit Gupta; Pradeep Kumar; Atul Sharma
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

Review 4.  Antibacterial activity study of 1,2,4-triazole derivatives.

Authors:  Feng Gao; Tengfei Wang; Jiaqi Xiao; Gang Huang
Journal:  Eur J Med Chem       Date:  2019-04-16       Impact factor: 6.514

Review 5.  Heterocyclic Scaffolds: Centrality in Anticancer Drug Development.

Authors:  Imran Ali; Mohammad Nadeem Lone; Zeid A Al-Othman; Abdulrahman Al-Warthan; Mohd Marsin Sanagi
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Authors:  Eva S Thomas; Henry L Gomez; Rubi K Li; Hyun-Cheol Chung; Luis E Fein; Valorie F Chan; Jacek Jassem; Xavier B Pivot; Judith V Klimovsky; Fernando Hurtado de Mendoza; Binghe Xu; Mario Campone; Guillermo L Lerzo; Ronald A Peck; Pralay Mukhopadhyay; Linda T Vahdat; Henri H Roché
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

7.  Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Authors:  Han-Jie Zhou; Monette A Aujay; Mark K Bennett; Maya Dajee; Susan D Demo; Ying Fang; Mark N Ho; Jing Jiang; Christopher J Kirk; Guy J Laidig; Evan R Lewis; Yan Lu; Tony Muchamuel; Francesco Parlati; Eileen Ring; Kevin D Shenk; Jamie Shields; Peter J Shwonek; Timothy Stanton; Congcong M Sun; Catherine Sylvain; Tina M Woo; Jinfu Yang
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

8.  Single-stage synthesis of heterocyclic alkaloid-like compounds from (+)-camphoric acid and their antiviral activity.

Authors:  Vladimir V Chernyshov; Olga I Yarovaya; Dmitry S Fadeev; Yuriy V Gatilov; Yana L Esaulkova; Anna S Muryleva; Katherina O Sinegubova; Vladimir V Zarubaev; Nariman F Salakhutdinov
Journal:  Mol Divers       Date:  2019-02-28       Impact factor: 2.943

Review 9.  Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box.

Authors:  Pedro Martins; João Jesus; Sofia Santos; Luis R Raposo; Catarina Roma-Rodrigues; Pedro Viana Baptista; Alexandra R Fernandes
Journal:  Molecules       Date:  2015-09-16       Impact factor: 4.411

Review 10.  Benzothiazole derivatives as anticancer agents.

Authors:  Ali Irfan; Fozia Batool; Syeda Andleeb Zahra Naqvi; Amjad Islam; Sameh M Osman; Alessio Nocentini; Siham A Alissa; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.